Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms.
Summary of "Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms."
Most cardiopulmonary diseases share at least one symptom with pulmonary embolism (PE). The aim of this study was to identify the most common acute causes of dyspnea, chest pain, fainting or palpitations, which diagnostic procedures were performed and whether clinicians investigate them appropriately. An Italian multicenter collaboration gathered 17,497 Emergency Department (ED) records of patients admitted from January 2007 to June 2007 in six hospitals. A block random sampling procedure was applied to select 800 hospitalised patients. Results of the overall 17,497 patients were obtained by weighting sampled cases according to the probability of the randomisation block variables in the whole population. The case-mix of enrolled patients was assessed in terms of cardiopulmonary symptoms, and the prevalence of acute disorders. The actual performance of procedures was compared with a measure of their accuracy as expected in the most common clinical presentations. PE occurred in less than 4% of patients with cardiopulmonary symptoms. Acute heart failure, pneumonia and chronic obstructive pulmonary disease exacerbation were the most likely diagnoses in patients with dyspnea. Acute myocardial infarction was present in roughly 10% of patients with chest pain. Atrial fibrillation was the prevalent diagnosis in patients with palpitations. Echocardiography, computed tomographic pulmonary angiography, perfusion lung scan, D-dimer test and B-type natriuretic peptide were performed less than expected from their accuracy. Diagnostic strategies, starting from non-specific symptoms and coping with the eventuality of PE, are likely to benefit from an increased awareness of the examination's accuracy in discriminating among several competing hypotheses, rather than in testing the single PE suspicion.
Affiliation
Department of Clinical Medicine, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy, alexsquizzo@libero.it.
Journal Details
This article was published in the following journal.
Name: Internal and emergency medicine
ISSN: 1970-9366
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22094406
- DOI: http://dx.doi.org/10.1007/s11739-011-0725-1
Medical and Biotech [MESH] Definitions
Pulmonary Heart Disease
Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM.
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
Warfarin
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Calorimetry, Differential Scanning
Differential thermal analysis in which the sample compartment of the apparatus is a differential calorimeter, allowing an exact measure of the heat of transition independent of the specific heat, thermal conductivity, and other variables of the sample.
Monocrotaline
A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.
PubMed Articles
To the Editor: In their review article, Agnelli and Becattini (July 15 issue)(1) discuss many important topics in acute pulmonary embolism. We would like to highlight the importance of the use of pulm...
To the Editor: In their review article, Agnelli and Becattini (July 15 issue)(1) discuss many important topics in acute pulmonary embolism. We would like to highlight the importance of the use of pulm...
To the Editor: In their review article, Agnelli and Becattini (July 15 issue)(1) discuss many important topics in acute pulmonary embolism. We would like to highlight the importance of the use of pulm...
To the Editor: In their review article, Agnelli and Becattini (July 15 issue)(1) discuss many important topics in acute pulmonary embolism. We would like to highlight the importance of the use of pulm...
To the Editor: In their review article, Agnelli and Becattini (July 15 issue)(1) discuss many important topics in acute pulmonary embolism. We would like to highlight the importance of the use of pulm...
Clinical Trials
Study of Diagnosis and Pathophysiology of Pulmonary Embolism (APE 1 Trial)
The purpose of this study is to - investigate which method and criterion for diagnosing pulmonary embolism is the best and - determine the relationship between blood ves...
Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)
To evaluate the sensitivity and specificity of two major, widely used technologies, radionuclear imaging (ventilation-perfusion scanning) and pulmonary angiography, for the diagnosis of pu...
PEITHO Pulmonary Embolism Thrombolysis Study
Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right...
Canadian Pulmonary Embolism Diagnosis Study (CANPEDS)
The main objective of the trial is to determine whether D-dimer testing combined with assessment of Pre-Test-Probability (using a standardized clinical model) can be used to markedly simpl...
Identifying Low-Risk Patients With Pulmonary Embolism
To develop a clinical prediction rule to identify patients with acute pulmonary embolism who are at very low risk for short-term adverse outcomes.